Compare RAPP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | PCRX |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2024 | 2011 |
| Metric | RAPP | PCRX |
|---|---|---|
| Price | $26.92 | $19.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $47.80 | $35.33 |
| AVG Volume (30 Days) | 427.2K | ★ 995.1K |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.21 |
| Revenue Next Year | N/A | $8.26 |
| P/E Ratio | ★ N/A | $43.81 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $6.43 | $19.84 |
| 52 Week High | $42.27 | $27.64 |
| Indicator | RAPP | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 25.61 |
| Support Level | $26.30 | $22.52 |
| Resistance Level | $28.10 | $22.56 |
| Average True Range (ATR) | 1.80 | 1.30 |
| MACD | -0.37 | -0.73 |
| Stochastic Oscillator | 20.07 | 2.92 |
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.